Soft Tissue Sarcoma Market to grow at a CAGR of 6.72% during 2025 to 2035; Driven by Rising Sarcoma Incidence and Increasing Adoption of Advanced Cancer Treatments

Market Highlights

The Soft Tissue Sarcoma Market Size was valued at USD 1.4 Billion in 2024. The market is projected to grow from USD 1.494 Billion in 2025 to USD 2.864 Billion by 2035, registering a CAGR of 6.72% during the forecast 2025–2035.

The increasing incidence of soft tissue sarcomas is significantly driving the growth of the market for related treatments and diagnostics. As the prevalence of these rare cancers rises, fueled by factors such as genetic predispositions, environmental influences, and lifestyle changes, there is a growing demand for innovative therapeutic options and advanced diagnostic technologies.

For instance, the American Cancer Society's estimated for soft tissue sarcomas in the United States for 2024 indicate a concerning trend, with approximately 13,590 new cases expected to be diagnosed, including 7,700 in males and 5,890 in females. This growing incidence underscores the urgency for improved treatment options and early detection strategies, as about 5,200 individuals (2,760 males and 2,440 females) are projected to succumb to the disease.

Moreover, according to Cancer Research UK, approximately 4,300 new cases of soft tissue sarcoma diagnosed in England each year, equating to around 12 cases per day based on data from 2017-2019. The incidence rates are notably highest among individuals aged 80-84, reflecting the increased vulnerability of older populations.

Further, since the period from 2013 to 2015, there has been a 5% increase in the incidence rates of soft tissue sarcoma in England, indicating a rising trend in cases. Furthermore, according to the Canadian Cancer Society, it is estimated that in 2024, around 1,700 Canadians diagnosed with soft tissue sarcoma, which includes cases affecting the heart. Among these, approximately 960 men and 730 women were expected to be diagnosed.

Moreover, according to the World Cancer Research Fund (WCRF) International, there were 35,813 cases of Kaposi sarcoma diagnosed globally in 2022. Of these cases, approximately 24,620 were in men, while 11,193 were in women. Additionally, According to Sarcoma UK, the most common subtype of soft tissue sarcoma is gastrointestinal stromal tumors (GIST), with 927 cases diagnosed in 2019, representing nearly 1 in 5 of all sarcomas diagnosed. Following GIST, the most frequently occurring subtypes include undifferentiated sarcoma, leiomyosarcoma, and liposarcoma. the rising incidence of soft tissue sarcomas is propelling growth in the global market for treatments and diagnostics.

Segment Analysis

The Global Soft Tissue Sarcoma Market has been segmented based on By Product, By Technology, By End User.

Based on type, the global soft tissue sarcoma market has been segmented into Angiosarcoma, Epithelioid Sarcoma, Gastrointestinal Stromal Tumor (GIST) and Others. The Angiosarcoma segment held the largest market in 2024 and the Gastrointestinal Stromal Tumor (GIST) segment is the fastest growing segment during the forecast period.

Based on Diagnosis and Treatment, the Global Soft Tissue Sarcoma Market has been segmented into Diagnosis and Treatment. The Diagnostic segment held the largest market in 2024 and the Treatment segment is the fastest growing segment during the forecast period. Diagnosis further segmented into Biopsy, Ultrasound Scan, Magnetic Resonance Imaging (MRI), and others which include PET scan, X- Ray. Treatment further segmented into Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, and Surgery.

Based on End User, the Global Soft Tissue Sarcoma Market has been segmented into Hospitals and Clinics, Cancer Research Centers and others. The Hospitals and Clinics segment held the largest market in 2024 and is the fastest growing segment during the forecast period.

Regional Analysis

North America leads in the Soft Tissue Sarcoma MarketSize, accounting for over 42.06% of the global revenue in 2024, increasing incidence rates, and significant investments in research and development. The region holds approximately 45% of the global market share, making it the largest market for soft tissue sarcoma treatments. Regulatory support from agencies like the FDA further catalyzes market growth, ensuring timely access to innovative therapies.

Europe Soft Tissue Sarcoma Marketwas valued at USD 0.42 billion in 2024, making it the second-largest regional market with a 30% share, driven by increasing awareness, improved diagnostic techniques, and supportive regulatory frameworks. The region accounts for approximately 30% of the global market share, making it the second-largest market. The European Medicines Agency (EMA) plays a crucial role in facilitating the approval of innovative therapies, which is essential for meeting the growing demand for effective treatments.

Key Findings of the Study

• The emergence of targeted therapies is reshaping treatment paradigms in the Soft Tissue Sarcoma Market.


• North America remains the largest market, while the Asia-Pacific region is recognized as the fastest-growing area for soft tissue sarcoma treatments.


• Gastrointestinal Stromal Tumor (GIST) represents the largest segment, whereas Angiosarcoma is noted for its rapid growth.


• Rising incidence of soft tissue sarcoma and advancements in diagnostic techniques are key drivers propelling market expansion.